Abstract
A new dihydropyranexanthone derived from the natural xanthone lichexanthone (1) was synthesised and, together with other 18 derivatives including ω-bromo and ω-aminoalkoxylxanthones (containing methyl, ethyl, propyl, tertbutylamino and piperidinyl moieties), were tested against Mycobacterium tuberculosis. Nine ω-aminoalkoxylxanthones showed good antimycobacterial activity, and their in vitro cytotoxicity was determined using VERO cells in order to calculate the selectivity index (SI). One of these nitrogenated xanthone derivatives showed very promising results, with MIC of 2.6 μM and SI of 48. This MIC is comparable to values found in “first and second line” drugs commonly used to treat TB. In order to understand better about this compound, it was evaluated together with two other ones that showed good SI, against resistant clinical strains of M. tuberculosis to verify the existence of cross-resistance. A chemometrical approach was useful to establish a pattern of antitubercular activity among the group of ω-aminoalkoxylxanthones, according to some structural and chemical features.
Keywords: Chemometrics, lichen, structural modifications, tuberculosis, xanthone.
Medicinal Chemistry
Title:Increment of Antimycobaterial Activity on Lichexanthone Derivatives
Volume: 9 Issue: 7
Author(s): Ana Camila Micheletti, Neli Kika Honda, Fernando R. Pavan, Clarice Q. F. Leite, Maria de Fatima Cepa Matos, Renata Trentin Perdomo, Danielle Bogo, Glaucia Braz Alcantara and Adilson Beatriz
Affiliation:
Keywords: Chemometrics, lichen, structural modifications, tuberculosis, xanthone.
Abstract: A new dihydropyranexanthone derived from the natural xanthone lichexanthone (1) was synthesised and, together with other 18 derivatives including ω-bromo and ω-aminoalkoxylxanthones (containing methyl, ethyl, propyl, tertbutylamino and piperidinyl moieties), were tested against Mycobacterium tuberculosis. Nine ω-aminoalkoxylxanthones showed good antimycobacterial activity, and their in vitro cytotoxicity was determined using VERO cells in order to calculate the selectivity index (SI). One of these nitrogenated xanthone derivatives showed very promising results, with MIC of 2.6 μM and SI of 48. This MIC is comparable to values found in “first and second line” drugs commonly used to treat TB. In order to understand better about this compound, it was evaluated together with two other ones that showed good SI, against resistant clinical strains of M. tuberculosis to verify the existence of cross-resistance. A chemometrical approach was useful to establish a pattern of antitubercular activity among the group of ω-aminoalkoxylxanthones, according to some structural and chemical features.
Export Options
About this article
Cite this article as:
Micheletti Camila Ana, Honda Kika Neli, Pavan R. Fernando, Leite Q. F. Clarice, Matos de Fatima Cepa Maria, Perdomo Trentin Renata, Bogo Danielle, Alcantara Braz Glaucia and Beatriz Adilson, Increment of Antimycobaterial Activity on Lichexanthone Derivatives, Medicinal Chemistry 2013; 9 (7) . https://dx.doi.org/10.2174/1573406411309070003
DOI https://dx.doi.org/10.2174/1573406411309070003 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of L5-7 Loop in the Structure and Chaperone Function of SsHSP14.1
Protein & Peptide Letters Prevalence of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients Attending Chest Clinics in Osun-State, Nigeria
Current Pharmaceutical Biotechnology Recent Progress Towards the Identification of Inhibitors of Mycobacterial Cell Wall Polysaccharide Biosynthesis
Mini-Reviews in Medicinal Chemistry Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry HIV Vaccine Efficacy and Immune Correlates of Risk
Current HIV Research Treatment Failure in Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Multifunctional Enzymes as Targets for the Treatment of Tuberculosis: Paving the Way for New Anti-TB Drugs
Current Medicinal Chemistry Quinoline Containing Side-chain Antimalarial Analogs: Recent Advances and Therapeutic Application
Current Topics in Medicinal Chemistry Novel 2-(2-Benzylidenehydrazinyl)Benzo[d]Thiazole as Potential Antitubercular Agents
Combinatorial Chemistry & High Throughput Screening Cardiac Morbidity in an HIV-1 Lipodystrophy Patient Cohort Expressing the TNF-α-238 G/A Single Nucleotide Gene Polymorphism
Current HIV Research Graphical Abstracts
Letters in Drug Design & Discovery Network-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Current Pharmaceutical Design Neuroimmunomodulation and Aging: A Role for Transferrin and the Hypothalamus/Thymus Axis
Current Aging Science Proteomic Profiling of Maternal Serum for Early Risk Analysis of Preterm Birth
Current Proteomics Hepatitis C Viruss Immune Evasion Strategies
Current Immunology Reviews (Discontinued) Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Energy Provisioning and Inflammasome Activation: The Pivotal Role of AMPK in Sterile Inflammation and Associated Metabolic Disorders
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design LC-MS/MS Assay for Quantification of a Novel Antitubercular Molecule S006-830: Pharmacokinetic and Plasma Protein Binding Studies in Rats
Current Pharmaceutical Analysis